Iodotope Therapeutic

Iodotope Therapeutics is an emerging biotechnology company focused on the development of next-generation targeted radiopharmaceuticals for the treatment of cancer. The company leverages a proprietary platform designed to optimize the delivery and stability of iodine isotopes, such as Iodine-131, to malignant tissues while minimizing off-target effects. By combining advanced radiochemistry with high-affinity targeting ligands, Iodotope aims to address the limitations of traditional radio-iodine therapies, such as deiodination. Led by industry veterans with extensive experience in nuclear medicine and oncology, the company is currently advancing its pipeline through pre-clinical development. Their approach centers on a theranostic model, utilizing specific iodine isotopes for both precise imaging and potent therapy.